Matinas BioPharma
MTNB
65 hedge funds and large institutions have $36.7M invested in Matinas BioPharma in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 11 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
14% more capital invested
Capital invested by funds: $32M → $36.7M (+$4.64M)
0.06% less ownership
Funds ownership: 0.54% → 0.48% (-0.06%)
4% less funds holding
Funds holding: 68 → 65 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$467K |
| 2 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$460K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$288K |
| 4 |
Two Sigma Advisers
New York
|
+$225K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$2.05M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.27M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$775K |
| 4 |
Renaissance Technologies
New York
|
-$581K |
| 5 |
Morgan Stanley
New York
|
-$542K |
MTNB Hedge Fund Activity: Q2 2020 in Review
65 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2020, worth a combined $36.7M — up 14% from $32M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MTNB and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 16 added.
The largest buyer was Two Sigma Investments, adding an estimated $467K. The largest seller was Victory Capital Management, cutting an estimated $2.05M.
- 65 institutional investors held Matinas BioPharma (MTNB) as of Q2 2020, down from 68 in Q1 2020.
- Funds reported $36.7M of Matinas BioPharma stock for Q2 2020, up 14% quarter-over-quarter.
- 8 funds opened new Matinas BioPharma positions in Q2 2020 and 11 closed out, a net change of -3 holders.
- The largest Matinas BioPharma buyer in Q2 2020 was Two Sigma Investments, an estimated $467K added.
- The largest Matinas BioPharma seller in Q2 2020 was Victory Capital Management, an estimated $2.05M sold.
Based on aggregated 13F filings for Q2 2020.